[go: up one dir, main page]

FR3107897B1 - Dérivés de nicotinamide mononucléotides - Google Patents

Dérivés de nicotinamide mononucléotides Download PDF

Info

Publication number
FR3107897B1
FR3107897B1 FR2002267A FR2002267A FR3107897B1 FR 3107897 B1 FR3107897 B1 FR 3107897B1 FR 2002267 A FR2002267 A FR 2002267A FR 2002267 A FR2002267 A FR 2002267A FR 3107897 B1 FR3107897 B1 FR 3107897B1
Authority
FR
France
Prior art keywords
nicotinamide mononucleotide
mononucleotide derivatives
derivatives
nicotinamide
arrhythmia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2002267A
Other languages
English (en)
Other versions
FR3107897A1 (fr
Inventor
Guillaume Bermond
Laurent Garçon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvamid SA
Original Assignee
Nuvamid SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2002267A priority Critical patent/FR3107897B1/fr
Application filed by Nuvamid SA filed Critical Nuvamid SA
Priority to PCT/EP2021/055676 priority patent/WO2021176093A1/fr
Priority to AU2021231328A priority patent/AU2021231328A1/en
Priority to US17/908,337 priority patent/US20230097603A1/en
Priority to CA3170031A priority patent/CA3170031A1/fr
Priority to JP2022553059A priority patent/JP2023517541A/ja
Priority to EP21709040.6A priority patent/EP4114408A1/fr
Priority to CN202180019077.1A priority patent/CN115605210A/zh
Publication of FR3107897A1 publication Critical patent/FR3107897A1/fr
Application granted granted Critical
Publication of FR3107897B1 publication Critical patent/FR3107897B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

DÉRIVÉS DE NICOTINAMIDE MONONUCLÉOTIDES La présente invention concerne un composé de formule (I) ou un sel et/ou solvate pharmaceutiquement acceptable de celui-ci ; (I) dans lequel X, R1, R2, R3, R4, R5, R6, R7, R8, Y, et sont tels que décrits dans les revendications, pour son utilisation dans le traitement et/ou la prévention de l’arythmie.
FR2002267A 2020-03-06 2020-03-06 Dérivés de nicotinamide mononucléotides Active FR3107897B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR2002267A FR3107897B1 (fr) 2020-03-06 2020-03-06 Dérivés de nicotinamide mononucléotides
AU2021231328A AU2021231328A1 (en) 2020-03-06 2021-03-05 Nicotinamide mononucleotide derivatives for the treatment of arrhythmia
US17/908,337 US20230097603A1 (en) 2020-03-06 2021-03-05 Nicotinamide mononucleotide derivatives for the treatment of arrhythmia
CA3170031A CA3170031A1 (fr) 2020-03-06 2021-03-05 Derives de nicotinamide mononucleotide et de bis-nicotinamide dinucleotide pour le traitement de l'arythmie
PCT/EP2021/055676 WO2021176093A1 (fr) 2020-03-06 2021-03-05 Dérivés de nicotinamide mononucléotide et de bis-nicotinamide dinucléotide pour le traitement de l'arythmie
JP2022553059A JP2023517541A (ja) 2020-03-06 2021-03-05 不整脈の治療のためのニコチンアミドモノヌクレオチド誘導体
EP21709040.6A EP4114408A1 (fr) 2020-03-06 2021-03-05 Dérivés de nicotinamide mononucléotide et de bis-nicotinamide dinucléotide pour le traitement de l'arythmie
CN202180019077.1A CN115605210A (zh) 2020-03-06 2021-03-05 用于治疗心律失常的烟酰胺单核苷酸和双烟酰胺二核苷酸衍生物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2002267 2020-03-06
FR2002267A FR3107897B1 (fr) 2020-03-06 2020-03-06 Dérivés de nicotinamide mononucléotides

Publications (2)

Publication Number Publication Date
FR3107897A1 FR3107897A1 (fr) 2021-09-10
FR3107897B1 true FR3107897B1 (fr) 2023-05-26

Family

ID=70614192

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2002267A Active FR3107897B1 (fr) 2020-03-06 2020-03-06 Dérivés de nicotinamide mononucléotides

Country Status (8)

Country Link
US (1) US20230097603A1 (fr)
EP (1) EP4114408A1 (fr)
JP (1) JP2023517541A (fr)
CN (1) CN115605210A (fr)
AU (1) AU2021231328A1 (fr)
CA (1) CA3170031A1 (fr)
FR (1) FR3107897B1 (fr)
WO (1) WO2021176093A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022129536A1 (fr) 2020-12-18 2022-06-23 Nuvamid Sa Dérivés de nicotinamide mononucléotide et leur utilisation dans la stimulation de l'expression de l'hémoglobine foetale
CA3222984A1 (fr) * 2021-06-17 2022-12-22 Laurent GARCON Derives mononucleotidiques nicotinamides et leur utilisation pour le traitement de l'insuffisance cardiaque a fraction d'ejection preservee
CN116987064B (zh) * 2023-08-04 2024-01-26 宁夏佰斯特医药化工有限公司 一种嘧啶双烟酰胺衍生物的制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106715455A (zh) * 2014-06-06 2017-05-24 葛兰素史密斯克莱知识产权（第2 号）有限公司 烟酰胺核苷类似物及其药物组合物和用途
EP3331894B1 (fr) * 2015-08-05 2021-02-17 Metro International Biotech, LLC Dérivés de nicotinamide mononucléotide et leur utilisations
WO2018002215A1 (fr) * 2016-06-30 2018-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de cardiomyopathies
US11071747B2 (en) * 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
EP3765010A2 (fr) * 2018-03-13 2021-01-20 Nuchido Limited Méthode de traitement
US10618927B1 (en) * 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide

Also Published As

Publication number Publication date
WO2021176093A1 (fr) 2021-09-10
FR3107897A1 (fr) 2021-09-10
US20230097603A1 (en) 2023-03-30
AU2021231328A1 (en) 2022-09-15
JP2023517541A (ja) 2023-04-26
CA3170031A1 (fr) 2021-09-10
CN115605210A (zh) 2023-01-13
EP4114408A1 (fr) 2023-01-11

Similar Documents

Publication Publication Date Title
FR3107897B1 (fr) Dérivés de nicotinamide mononucléotides
MA32231B1 (fr) Composés organiques
LT3953330T (lt) Nitrilo turintys junginiai, naudingi kaip antivirusiniai agentai, skirti koronavirusinei infekcijai gydyti
MA65131A1 (fr) Utilisation d'un inhibiteur d'ezh2 dans la préparation d'un médicament pour le traitement d'un lymphome à cellules t
MX2022001671A (es) Sales de un inhibidor de pd-1/pd-l1.
MA52360B1 (fr) Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines
JOP20220101A1 (ar) مثبطات صغيرة الجزئ لطافر G12C لبروتين ساركوما جرذان Kirsten (KRAS)
MA46038B1 (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
MA41338A (fr) Composés de pyrazine pour le traitement de maladies infectieuses
MA42292B1 (fr) Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b
CR20200588A (es) Compuestos novedosos
MA42795A (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA32965B1 (fr) Derives de sulfonamides
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih
MA29926B1 (fr) Derives de pyrazine
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA45020A (fr) Dérivés sulfonamides aromatiques
AR087046A2 (es) Compuestos derivados de 4-oxoquinolina
JP2016518437A5 (fr)
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210910

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6